Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MHLW To Add 100 Adverse Event Analysts

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor and Welfare has put out a new plan to recruit 100 drug adverse effect analysts to strengthen such functions at the Pharmaceutical and Medical Device Agency. PMDA handles drug reviews and post market inspections. The increase will more than double the current 66 analysts who are conducting side effects analysis. The Ministry expects most of the new hires will be physicians, pharmacists and statisticians. As several highly effective cancer and rheumatic drugs have been launched to the market, the Ministry estimates that associated adverse events reports will be on the rise. (Click here for more - Japanese language

You may also be interested in...



Japan Pharmaceutical Trade Association Helps Foot Bill To Speed Up Approval Of Drugs Pending Approval

The Japan Pharmaceutical Manufacturer's Association announced a plan to establish a support center to speed up approvals of drugs not yet approved in Japan. With an annual budget of ¥310 million and staffed with Japanese academics and pharmaceutical industry veterans, the center is opening its doors this month

Austria’s Apeiron To Attack COVID-19 At Its Entry Point

Apeiron Biologics has fashioned a recombinant version of the enzyme to which SARS-CoV-2 is thought to bind, and with governmental help has started a Phase II study in Austria, Germany and Denmark. 
 
 
 

 

Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics

Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.

UsernamePublicRestriction

Register

SC069786

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel